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Abstract
Background: Hyperglycemia has recently been described as a risk factor for the development of retinopathy of
prematurity (ROP), a proliferative vascular disease of the retina that primarily affects premature infants. This study
was to evaluate the relationship of hyperglycemia and the development of ROP in premature infants less than
32 weeks gestation.
Methods: This was a retrospective cohort study of all infants less than 32 weeks gestation from 2003–2007 who
survived to discharge in our NICU. Demographic data including birthweight, gestational age, Apgar scores, method
of delivery, antenatal steroid use, neonatal steroid use, and size for gestational age was collected for each infant.
Episodes of sepsis, grade of intraventricular hemorrhage, presence of a patent ductus arteriosus, number of days on
the ventilator, and stage of necrotizing enterocolitis were assessed as well as days of hyperglycemia, defined as
number of days with whole blood glucose > 150 mg/dl. In addition, the highest stage of ROP was recorded for
each infant. A Student’s two tailed t-test or Fisher’s exact test was performed to identify significant clinical risk
factors associated with the development of ROP. From this univariate analysis, a multiple logistic regression was
performed to determine the effect of hyperglycemia on the development of ROP, adjusting for significant clinical
risk factors. Statistical analysis was performed using SAS v.9.2.
Results: Univariate analysis demonstrated that infants with ROP were of lower birthweight and gestational age, and
were affected by a patent ductus arteriosus, neonatal sepsis, intraventricular hemorrhage, have significant lung
disease and received postnatal glucocorticoid therapy. Infants with ROP experienced more days with hyperglycemia
(7 vs. 2, p = < 0.0001). Using multiple logistic regression analysis to compare no ROP vs. all stages of ROP,
gestational age (OR 0.745, 95% CI [0.634, 0.877], p = 0.0004), mean days of hyperglycemia (OR 1.073, 95% CI [1.004,
1.146], p = 0.04), and mean days receiving mechanical ventilation (OR 1.012, 95% CI [1.000, 1.025], p = 0.05)
remained significantly associated with ROP after adjusting for other risk factors.
Conclusion: Our data suggests that hyperglycemia is associated with the development of ROP in premature
infants.
Keywords: Prematurity, Retinopathy of prematurity, Hyperglycemia

Background
Retinopathy of prematurity (ROP) is a proliferative vascular
disease of the retina that primarily affects premature
infants and is one of the leading causes of visual loss
in children [1]. Premature infants that are born at low
birth weight or at a lower gestational age are particularly
vulnerable [2].
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In addition to genetic risk factors that are associated
with the development of ROP [3-5], there are well
established environmental risk factors for ROP, including
early oxygen exposure and extreme prematurity [6].
Hyperglycemia is a newly reported environmental risk
factor for ROP. Hyperglycemia, commonly defined as
whole blood glucose level greater than 125 mg/dl or
plasma glucose level greater than 150 mg/dl, occurs
frequently in premature infants. In a study by Dweck
et al., it was found that 86% of infants with a birthweight
less than 1100 grams were hyperglycemic, with the
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highest risk of being hyperglycemic occurring within the
first 24 hours of birth [7]. Data from a cohort analyses of
the NIRTURE study also demonstrated that 80% of very
low birth weight infants had glucose levels > 8 mmol/L
(>144 mg/dL) and 32% had glucose levels > 10 mmol/L
(>180 mg/dL) >10% of the time in the first week of life [8].
Recent studies have shown an association between
neonatal hyperglycemia and (1) increased risk of early
death and morbidity in extremely low birth weight
infants [9,10], (2) increased morbidity and mortality in
premature infants with necrotizing enterocolitis [11],
and (3) has also been shown to be a risk factor for death
and white matter reduction in preterm infants [12]. In
addition, previous studies have demonstrated an association
between hyperglycemia and the development of ROP
[13-15]. The purpose of this study was to evaluate the
relationship between the duration of hyperglycemia and
the development of ROP in a larger cohort of premature
infants born at less than 32 weeks gestation.

Methods
We performed a retrospective cohort study examining the
relationship between hyperglycemia and development of
ROP, adjusting for multiple risk factors. A retrospective
chart review was performed of all infants less than
32 weeks gestational age admitted to the Neonatal Intensive
Care Unit at the University of Iowa Children’s Hospital
from 2003–2007 who had ophthalmologic screening for
ROP. Initial ophthalmologic screening was performed on
all patients with gestational age less than 32 weeks or
birthweight less than 1500 gram and follow up was at the
discretion of the ophthalmologist. ROP severity was staged
by the International Classification of ROP [16] and the
highest stage of ROP was recorded.
Subject demographic information (birth weight, gestational age, Apgar scores, gender, method of delivery, antenatal steroid use, neonatal steroid use, size for gestational
age) was extracted from the patient’s medical records.
Episodes of sepsis, presence of intraventricular hemorrhage
(IVH), presence of a patent ductus arteriosus (PDA),
necrotizing enterocolitis (NEC, ≥ Bell’s Stage II) [17],
and number of days of ventilator support were recorded
as well. Sepsis was defined as any positive culture (blood,
urine, or cerebrospinal fluid) that occurred at any
point during the hospital stay. IVH was graded by the
attending pediatric radiologist and the highest grade
was recorded. The presence of a PDA was determined
by standard echocardiography performed by a pediatric
cardiologist according to our NICU clinical guidelines.
All infants < 28 weeks gestation were evaluated for PDA
between days of life 5 through 7 regardless of symptoms,
and infants ≥ 28 weeks gestation were evaluated between
days of life 5 through 7 if the infant had a murmur
consistent with a PDA.
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In this study, hyperglycemia was defined as the number
of days with at least one whole blood glucose level greater
than 150 mg/dl. Glucose levels were determined from
whole blood using the glucose oxidation technique
(ABL800 Flex, Radiometer America Inc., USA). Days of
hyperglycemia was chosen for analysis rather than highest
recorded glucose level to minimize confounding due to
differences in the number of laboratory measurements
obtained in smaller, sicker infants as compared to larger,
healthier preterm infants.
Initial univariate analysis was performed to evaluate
individual clinical risk factors associated with the
development of ROP utilizing either a Student’s two tailed
t-test for comparison of means or Fisher’s exact test for
comparison of categorical values. From this initial univariate analysis, a multiple logistic regression analysis was
performed to determine the effect of hyperglycemia on
the development of ROP, adjusted for significant clinical
risk factors. We first modeled the relationship between of
any degree of ROP vs. no ROP, adjusting for clinical
factors found to be associated with ROP in univariate
analyses. This was the primary outcome of our study. In
addition, further analyses were performed to evaluate
the relationship of hyperglycemia to different degrees of
ROP. All statistical analysis was performed using SAS
v.9.2 (SAS Institute Inc., Cary, NC, USA). Approval of
the University of Iowa Institutional Review Board was
obtained to access the clinical information required for
this study.

Results
We identified 582 infants less than 32 weeks gestation
that underwent ophthalmologic screening for ROP.
Overall, 412 infants had no ROP and 170 had ROP (57
with Stage I, 65 with Stage II, and 48 with Stage III).
There were no cases of Stage IV or V ROP in this study
cohort. No infants in this trial received insulin therapy
for hyperglycemia.

Univariate analyses

Table 1 outlines the results of the univariate analysis. Not
surprisingly, infants diagnosed with ROP were of lower
birthweight and gestational age compared to those
without ROP, and were more likely to have been affected by
a PDA, neonatal sepsis, and intraventricular hemorrhage.
Infants with ROP were also more likely to have significant
lung disease and to have received postnatal glucocorticoid
therapy than those without ROP. There were no differences
between ROP and non-ROP subjects with respect to
rate of c-section delivery, gender, or NEC. Infants with
ROP experienced a greater mean number of days with
hyperglycemia (7 vs. 2, p = < 0.0001).
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Table 1 Clinical characteristics of study population

Table 3 Risk factors for development of stage 3 ROP
among all infants, n = 582*

No ROP
(n = 412)

Any ROP
(n = 170)

p-value

Clinical variable

Beta coeff Odds ratio 95% CI

1080 ± 272

831 ± 266

< 0.0001

Gestational age

−0.37

0.690

(0.533, 0.892) 0.04

Gestational age, weeks (mean)

28.1 ± 1.8

25.8 ± 1.9

< 0.0001

Hyperglycemia days 0.0003

1.000

(0.938, 1.066)

One minute APGAR (mean)

5.5 ± 2.3

4.4 ±2.2

< 0.0001

Ventilator days

0.0134

1.013

(1.001, 1.027) 0.04

Five minute APGAR (mean)

7.5 ± 1.5

6.5 ± 1.9

< 0.0001

Sepsis

0.562

1.756

(0.915, 3.4)

Male gender (%)

50.5

53.5

0.52

IVH

0.716

2.045

(1.017, 4.113) 0.04

C-section (%)

72.8

67.1

0.19

PDA

0.035

1.036

(0.702, 1.528)

0.86

Antenatal steroids (%)

90.7

87.3

0.15

Neonatal steroids

−0.072

0.931

(0.422, 2.054)

0.86

Small for gestational age (%)

15.6

13.5

0.53

Patent ductus arteriosus (%)

35.2

66.5

< 0.0001

Intraventricular hemorrhage (%)

18.2

31.8

< 0.0006

For all dichotomous predictor variables 1 = presence of risk factor, 0 = absence
of risk factor.
* no ROP, stage 1 or 2 ROP = 0, stage 3 ROP =1, probability modeled is stage
3 ROP = 1.

Necrotizing enterocolitis (%)

2.9

4.1

0.62

Neonatal sepsis (%)

20.6

42.4

< 0.0001

Neonatal steroid therapy (%)

14.6

50

< 0.0001

2.3 ± 3.2

7.1 ± 6.6

< 0.0001

17.0 ± 20.6

49.6 ± 47.7

< 0.0001

Birthweight gm (mean)

Hyperglycemia days (mean)
Ventilator days (mean)

Multiple logistic regression

From this univariate analysis, a multiple logistic regression
analysis was performed to analyze the association of hyperglycemia with ROP while adjusting for other significant
risk factors as shown in Tables 2, 3. We first modeled
ROP as any ROP vs. no ROP, including the whole study
population. In Table 2, when comparing no ROP vs. all
stages of ROP, gestational age (OR 0.745, 95% CI [0.634,
0.877], p = 0.0004), days of hyperglycemia (OR 1.073, 95%
CI [1.004, 1.146), p = 0.04], and days receiving mechanical
ventilation (OR 1.012, 95% CI [1.000, 1.025], p = 0.05)
remained significantly associated with ROP after adjusting
for other risk factors. Specific tests of multicollinearity were
not performed. The risk of being diagnosed with ROP
increased 7% for each additional day of hyperglycemia.
We then undertook further analyses to explore the
relationship of hyperglycemia to different degrees of
Table 2 Risk factors for the development of ROP, n = 582*
Clinical variable

Beta
coeff

Odds
ratio

95% CI

p-value

Gestational age , wks

−0.29

0.745

(0.634, 0.877)

0.0004

Hyperglycemia days

0.07

1.073

(1.004, 1.146)

0.04

Ventilator days

0.01

1.012

(1.000, 1.025)

0.05

Sepsis

0.18

1.195

(0.784, 1.823)

0.41

IVH

0.47

1.608

(0.975, 2.652)

0.06

PDA

0.12

1.130

(0.892, 1.432

0.31

Neonatal steroids

0.43

1.537

(0.904, 2.613)

0.11

For all dichotomous predictor variables 1 = presence of risk factor, 0 = absence
of risk factor.
* no ROP = 0, any ROP =1, probability modeled is ROP = 1.

p-value
0.99

0.09

ROP. We modeled risk factors associated with development
of severe (Stage III) ROP among all infants (Table 3).
Gestational age (OR 0.69, 95% CI [0.53, 0.90], p = 0.005),
ventilator days (OR 1.01, 95% CI [1.001, 1.027] p = 0.04),
and IVH (OR 2.0, 95% CI [1.01, 4.1] p = 0.044) were
significantly associated with ROP. We then modeled
development of severe ROP only among those infants
who developed any ROP (170 infants), and no significant
risk factors were identified. In neither model was hyperglycemia a risk factor for the development of severe ROP.

Discussion
This study demonstrates an association between duration
of hyperglycemia (defined as number of days with whole
blood glucose > 150 mg/dL) and the development of ROP
in premature infants less than 32 weeks gestational age.
There is emerging evidence that neonatal hyperglycemia
is a significant risk factor in neonatal morbidity and
mortality. In a study by Kao et al. evaluating hyperglycemia
and morbidity and mortality in extremely low birth weight
(ELBW) infants, it was seen that there was a relationship
between severe hyperglycemia (serum glucose > 180 mg/
dL) and an increased risk of death or sepsis [10]. In another
study by Hays et al., also evaluating hyperglycemia as a
risk factor for early death and morbidity in ELBW infants,
it was shown that neonatal hyperglycemia was significantly
associated with an increased risk of death or the development of Grade III/IV IVH [9].
Hyperglycemia has also been previously shown to be
associated with the development of ROP. In a study by
Garg et al. evaluating hyperglycemia and the development
of Stage III or IV ROP, it was shown that for each
10 mg/dL increase of mean serum glucose, there was
2.7-fold increase in the risk of developing ROP [14].
Blanco et al. also found that hyperglycemia was associated
with a 4.5-fold increase in the incidence of ROP in a
Hispanic population of ELBW infants [18]. In a recent
study by Kaempf et al., hyperglycemia and insulin
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exposure was shown to be associated with higher stages of
ROP [15]. In our study, we have shown that the duration
of hyperglycemia is a significant risk factor in the development of ROP, with each day of hyperglycemia increasing
the risk by 7% in a population of ELBW infants who did
not receive insulin therapy. Studying infants who did not
receive insulin therapy allowed us to investigate the role
of hyperglycemia in the incidence of ROP independently
of insulin exposure. Our study also shows that duration
of hyperglycemia is associated with ROP, building on
previous studies that chose highest glucose at one time
point to define hyperglycemia.
Interestingly, however, we were unable to establish an
association between duration of hyperglycemia and severe
(Stage III) ROP. Utilizing two different multiple logistic
regression models, duration of hyperglycemia was found
to not be associated with the development of severe (Stage
III) ROP. This is in contrast to Garg et al’s study, where
hyperglycemia, as defined by highest measured blood
glucose in the first month of life, was found to be associated
with the development of Stage III or IV ROP, although
they specifically chose to study the impact of glucose on
Stages III and IV and included infants with Stage I in the
control group of their case–control study. Similar to our
results, they also demonstrated a significantly higher
number of days with glucose measurements of > 150 mg/
dl among patients with ROP (8.4 days vs. 5.3 days,
p = 0.028), but did not include duration of hyperglycemia
in multivariable analysis [14].
In adults, hyperglycemia has been shown to play a
significant role in the development of proliferative diabetic
retinopathy [19]. Like ROP, proliferative diabetic retinopathy
is characterized by the development of new blood vessels
in the retina that can extend into the vitreous of the eye.
Additionally, similar to severe ROP, retinal detachment
can occur due to the fibrous contractile tissue that is
formed [20].
Hyperglycemia may influence ROP through its significant effect on retinal blood flow [21]. In diabetic rats,
reduction of glucose levels resulted in an improvement
in retinal blood flow when compared to diabetic rats who
remained hyperglycemic [22]. Additionally, hyperglycemia
has been shown to increase the formation of diacylglycerol,
which in turn increases activation of protein kinase C.
Protein kinase C has been shown to have an effect on many
different growth factors, such as vascular endothelial
growth factor (VEGF), which impacts angiogenesis and
vascular permeability [23]. Hyperglycemia, in hypoxic
culture conditions, has also been shown to increase VEGF
production in retinal Müller cells [24]. Additionally, in an
in vitro assay of VEGF production in cultured bovine
retinal pigmented epithelial cells, it was shown that those
cells that were exposed to a prolonged period of hyperglycemia had significantly elevated level of VEGF production
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when compared to controls [25]. While the factors that
lead to the progression of ROP are not well understood,
it is possible that the duration of hyperglycemia is a
factor in the initiation of ROP, but other factors such as
oxygen exposure and genetics have a more critical role in
influencing the factors that are involved in the progression
of the disease. As such, duration of hyperglycemia could
potentially be more of a risk factor for the development of
mild (Stage I) or moderate (Stage II) ROP rather than
severe (Stage III) ROP.
Our study is limited due to its retrospective nature.
Although we have shown an association between hyperglycemia and the development of ROP, we have not
presented evidence that is suggestive of causation.
The question remains whether hyperglycemia itself is
a definitive risk factor, or is a marker of significant illness.
We did adjust for other known risk factors which are
markers for more severe illness, but the possibility of
residual confounders is likely. However, using proliferative
diabetic retinopathy as a model of a proliferative vascular
retinal disease, it has been shown that hyperglycemia has
a significant impact on the development and progression
of the disease.

Conclusion
In conclusion, we have shown an association between
duration of hyperglycemia and the development of ROP
in premature infants less than 32 weeks gestation,
adjusting for multiple risk factors. As hyperglycemia is a
partially modifiable risk factor, further prospective studies
are needed to fully evaluate the impact of hyperglycemia
and the development of ROP.
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